← All trials
NCT04521686
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2020
- Primary completion
- Feb 28, 2023
- Completion date
- Sep 30, 2023
- First posted
- Aug 20, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 180
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Loxo OncologyLead sponsor
- Eli LillyCollaborator
- Antengene CorporationStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.